EP Patent

EP3789034A1 — Treatment of iron deficiency with soluble ferric pyrophosphate

Assigned to Charak LLC · Expires 2021-03-10 · 5y expired

What this patent protects

The invention provides for soluble ferric pyrophosphate in an amount effective to maintain or increase Hgb levels in the subject for use in methods of treating iron deficiency and in methods of reducing or eliminating the dose of erythropoiesis stimulating agent for increasing or…

USPTO Abstract

The invention provides for soluble ferric pyrophosphate in an amount effective to maintain or increase Hgb levels in the subject for use in methods of treating iron deficiency and in methods of reducing or eliminating the dose of erythropoiesis stimulating agent for increasing or maintaining hemoglobin levels in the target range in a subject suffering from anemia.

Drugs covered by this patent

Patent Metadata

Patent number
EP3789034A1
Jurisdiction
EP
Classification
—
Expires
2021-03-10
Drug substance claim
No
Drug product claim
No
Assignee
Charak LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.